Citigroup Reaffirms Buy Rating for Bayer (BAYN)
Bayer (FRA:BAYN)‘s stock had its “buy” rating reiterated by research analysts at Citigroup in a research report issued on Wednesday.
BAYN has been the topic of several other reports. Nord/LB restated a “neutral” rating on shares of Bayer in a research report on Wednesday, December 27th. DZ Bank restated a “buy” rating on shares of Bayer in a research report on Monday, December 11th. Barclays set a €105.00 ($125.00) target price on shares of Bayer and gave the stock a “sell” rating in a research report on Monday, November 6th. Independent Research set a €120.00 ($142.86) target price on shares of Bayer and gave the stock a “neutral” rating in a research report on Tuesday, November 28th. Finally, Warburg Research set a €121.00 ($144.05) target price on shares of Bayer and gave the stock a “neutral” rating in a research report on Thursday, January 11th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of €121.67 ($144.84).
Shares of Bayer (FRA BAYN) opened at €103.48 ($123.19) on Wednesday. The company has a market cap of $85,870.00 and a price-to-earnings ratio of 27.74. Bayer has a 1 year low of €99.69 ($118.68) and a 1 year high of €123.82 ($147.40).
COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/17/citigroup-reaffirms-buy-rating-for-bayer-bayn.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.